Organism Attribute – Page 2

CDC Orders Retraction of Research Papers and Removes Website Content Amid New Language Restrictions

6 months ago talkbio0Tagged Centers for Disease Control and Prevention (U.S.), Feeling content, Gender, Languages, LGBTQ+, removal technique, research retraction, restrictions, Scientific Publication, Sense of identity (observable entity), Web Site

CDC, research retraction, website content removal, language restrictions, LGBTQ, gender identity, scientific publications

First Lady Jill Biden Continues to Champion Women’s Health Research Beyond White House Tenure

6 months ago talkbio0Tagged ARPA-H, Gender, Health care facility, health research, Healthcare Disparities, Jill, White House Initiative, women 's

Jill Biden, women’s health research, White House Initiative, ARPA-H, healthcare disparities, gender gap in healthcare

Truveta Genome Project: A Historic 10M Genome Sequencing Initiative Backed by Regeneron, Illumina, and Leading Health Systems

6 months ago talkbio0Tagged Drug Discovery, genetic sequencing, genome sequencing, Genotype, healthcare analytics, Illumina, phenotypic, Precision Medicine, Regeneron, Truveta

Truveta Genome Project, 10M genome sequencing, Regeneron, Illumina, genetic sequencing, genotypic and phenotypic data, healthcare analytics, drug discovery, personalized medicine.

FDA Issues Complete Response Letter for Zealand Pharma’s Glepaglutide in Short Bowel Syndrome Treatment

7 months ago talkbio0Tagged Analog, Complete, Glepaglutide, Glucagon-Like Peptide 2, Rejection, Response process, Short Bowel Syndrome, United States Food and Drug Administration, Zealand Pharma

Zealand Pharma, Glepaglutide, GLP-2 analog, Short Bowel Syndrome (SBS), FDA rejection, Complete Response Letter

ASH 2024: Anito-cel Demonstrates Enhanced Response Rate and Consistent Safety in Phase II Update for Relapsed/Refractory Multiple Myeloma

8 months ago talkbio0Tagged 2024, anito-cel, Arcellx, Asymmetric Septal Hypertrophy, Phase II Update, Profiling (action), Rating (action), relapsed/refractory multiple myeloma, Response process, Safety

ASH 2024, Anito-cel, Arcellx, Relapsed/Refractory Multiple Myeloma, Phase II Update, Response Rate, Safety Profile

Biohaven’s Taldefgrobep Alfa Shifts Focus to Obesity After Missing Primary Endpoint in Spinal Muscular Atrophy Phase 3 Trial

8 months ago talkbio0Tagged Alfa, Body Composition, Bone and Bones, density, GDF8 protein, human, Inhibitor, lean, Obesity, Phase 3 trial, Spinal Muscular Atrophy

Biohaven, taldefgrobep alfa, spinal muscular atrophy (SMA), obesity, myostatin inhibitor, phase 3 trial, body composition, lean muscle mass, bone density.